Channel Infrastructure NZ Ltd

Cambridge Healthcare Innovations Unveils Quattrii Inhaler Technology to Deliver Large-Dose Biologics and mRNA Therapies

- Cambridge Healthcare Innovations has announced Quattrii, a dry powder inhaler engine capable of delivering large volumes of biologic and mRNA molecules in a single inhalation with at least 70% lung delivery efficiency. - The technology separates active drugs from lactose carriers during delivery, reducing inert powder inhalation and potentially enabling novel therapies for lung cancer, Parkinson's disease, and pain management. - Quattrii will be available for pharmaceutical companies to use in Phase 1 clinical trials starting Q4 2025, representing a significant advancement over existing inhalers that typically deliver only 10-50% of drugs to the lungs.